Altered Expression of Hepatic Cytochromes P-450 in Mice Deficient in One or More mdr1 Genes
- Erin G. Schuetz1,
- Diane R. Umbenhauer2,
- Kazuto Yasuda1,
- Cynthia Brimer1,
- Lan Nguyen1,
- Mary V. Relling1,
- John D. Schuetz1 and
- Alfred H. Schinkel3
- 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (E.G.S, K.Y., C.B., L.N., M.V.R., J.D.S.); 2Department of Safety Assessment Merck Research Laboratories, West Point, Pennsylvania (D.R.U.); and 3Division of Molecular Biology, the Netherlands Cancer Institute, Amsterdam, the Netherlands (A.H.S.)
Abstract
We hypothesized that the drug efflux protein P-glycoprotein (Pgp), the product of the multidrug resistance gene MDR1, might influence hepatic expression of CYP3A or other cytochromes P-450 (P-450s) because Pgp can transport endogenous regulators of these cytochromes. We began with variants of a CF-1 mouse strain containing a defective mdr1a gene that is inherited in a Mendelian fashion. The amount of CYP3A protein in liver was inversely related to the gene dose of the normal mdr1a allele in these mice.mdr1a knockout mice of either mixed (FVB × 129/Ola) or pure FVB genetic background and housed in Amsterdam display an increased expression of CYP2B and CYP3A proteins. However, becausemdr1a ablation causes a compensatory increase in hepaticmdr1b (which can efflux intracellular glucocorticoids), we reasoned that mdr1b might mask the overall effect ofmdr1a absence on P-450 gene expression. Targeted inactivation of the mdr1b gene increased P-450 expression, but the effect was modest compared withmdr1a ablation. Mice nullizygous for bothmdr1a and mdr1b-type Pgps and kept in Amsterdam had dramatically increased levels of CYP3A protein as well as other P-450s examined and of the electron donor P-450 reductase. Consistent with the protein results, CYP3A catalytic activity measured as midazolam 1′- and 4-hydroxylation in liver microsomes from these knockout mice revealed a rank order of activities withmdr1a/1b > mdr1a >mdr1b > (+/+) mice. In contrast to results in mice housed in Amsterdam, in the genetically identical mdr1aor mdr1a/1b (−/−) male mice housed in the United States, hepatic P-450 expression was unaffected by mdr1genotype or actually showed a slight decrease in mdr1a(−/−) mice. These results provide a revealing picture ofmdr1-type Pgp as an upstream regulator of hepatic P-450 expression, and demonstrate that these pharmacologically relevant phenotypes in knockout mice depend not only on the genetic make-up of the mice but also on the environment.
Footnotes
-
Send reprint requests to: Dr. Erin Schuetz, Dept. of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis TN 38105. E-mail:erin.schuetz{at}stjude.org
-
This work was supported by National Institute of Health Grants ES/GM 5851 and 8568, CA51001, and Core Grant CA21765, and by the American Lebanese Syrian Associated Charities.
- Abbreviations:
- P-450
- cytochrome P-450
- PXR
- pregnane X receptor
- P-450 reductase
- NADPH cytochrome P-450 reductase
- Pgp
- P-glycoprotein, the product of the human MDR1 and mousemdr1a and mdr1b genes
- MDR1
- multidrug resistance gene
-
- Received July 1, 1999.
- Accepted September 14, 1999.
- The American Society for Pharmacology and Experimental Therapeutics



